SEC Comment Letter for GT Biopharma, Inc. (GTBP) (CIK 0000109657) (GTBP) — May 9, 2017
GT Biopharma, Inc. (GTBP) (CIK 0000109657)
Date: May 9, 2017 · CIK: 0000109657 · Accession: 0000000000-17-016257
AI Filing Summary & Sentiment
Reasoning
Letter
Mail Stop 4546 May 9, 2017 Anthony J. Cataldo Chairman and CEO Oxis International, Inc. 100 South Ashley Drive, Suite 600 Tampa, Florida 33602
Re: Oxis International, Inc. Revised Preliminary Information Statement on Schedule 14C Filed May 5, 2017 File No. 000 -08092
Dear Mr. Cataldo :
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absen ce of action by the staff.
Sincerely,
/s/ Erin K. Jaskot, for
Show Raw Text
Mail Stop 4546 May 9, 2017 Anthony J. Cataldo Chairman and CEO Oxis International, Inc. 100 South Ashley Drive, Suite 600 Tampa, Florida 33602 Re: Oxis International, Inc. Revised Preliminary Information Statement on Schedule 14C Filed May 5, 2017 File No. 000 -08092 Dear Mr. Cataldo : We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absen ce of action by the staff. Sincerely, /s/ Erin K. Jaskot, for Suzanne Hayes Assistant Director Office of Healthcare and Insurance Cc: Gary R. Henrie